Open AccessAngioedema due to fixed dose combination of telmisartan plus ramipril
Author(s) -
Vishal R Tandon,
Annil Mahajan,
Vijay Khajuria,
Zahid Gillani
Publication year - 2014
Publication title -
journal of pharmacology and pharmacotherapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.301
H-Index - 34
eISSN - 0976-5018
pISSN - 0976-500X
DOI - 10.4103/0976-500x.136113
Subject(s) - olmesartan , angioedema , telmisartan , ramipril , medicine , aliskiren , losartan , valsartan , pharmacology , irbesartan , fixed dose combination , angiotensin ii , renin–angiotensin system , receptor , blood pressure
The risk for angioedema has been suggested lower with angiotensin receptor blockers (ARBs) than with angiotensin-converting enzyme inhibitors (ACEIs) or aliskiren. Many isolated reports do exist, reporting angioedema with ARBs such as olmesartan, valsartan, losartan and telmisartan. To the best of our knowledge this is the first case report of telmisartan plus ramipril fixed dose combination leading to angioedema from India questioning the rationality of ARBs plus ACEIs combination in the treatment of hypertension.